Drugs that contain Ciprofloxacin

1. Drug name - OTIPRIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9603796 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders
Apr, 2029

(6 years from now)

CN102099013A ALK ABELLO Controlled-Release Apoptosis Modulating Compositions And Methods For The Treatment Of Otic Disorders
Apr, 2013

(9 years ago)

CN102112111A ALK ABELLO Controlled Release Auris Sensory Cell Modulator Compositions And Methods For The Treatment Of Otic Disorders
Feb, 2017

(5 years ago)

CN102112112A ALK ABELLO Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
Mar, 2017

(5 years ago)

CN104940126A ALK ABELLO Control Release Type Ear Structure Adjusting And Congenital Immune System Adjusting Composition, Device And Method For Treating Ear Disease
Aug, 2018

(4 years ago)

CN102105133B ALK ABELLO Control-Release-Type Ear Structure Regulation And Congenital Immune System Regulating Composition And Method For Treating Otic Disorders
Jul, 2019

(3 years ago)

CN102105133A ALK ABELLO Controlled-Release Otic Structure Modulating And Innate Immune System Modulating Compositions And Methods For The Treatment Of Otic Disorders
Jul, 2019

(3 years ago)

CN102014957B ALK ABELLO For Otic Formulations For Treating Otic Diseases And Conditions
Apr, 2021

(1 year, 5 months ago)

CN102014957A ALK ABELLO Auris Formulations For Treating Otic Diseases And Conditions
Apr, 2021

(1 year, 5 months ago)

CN103417472B ALK ABELLO A Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
Apr, 2022

(5 months ago)

CN103417472A ALK ABELLO A Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
Apr, 2022

(5 months ago)

CN102026623A ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

CN102026623B ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

CN104352429A ALK ABELLO Controlled Release Antimicrobial Composition And Method For Treating Ear Part Condition
Jul, 2029

(6 years from now)

CN104352429B ALK ABELLO For Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
Jul, 2029

(6 years from now)

EP2303227A2 ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

EP2303227B1 ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

EP2303227A4 ALK ABELLO Controlled Release Corticosteroid Compositions And Methods For The Treatment Of Otic Disorders
May, 2029

(6 years from now)

EP2299979A4 ALK ABELLO Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
Jul, 2029

(6 years from now)

EP2299979B1 ALK ABELLO Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
Jul, 2029

(6 years from now)

EP2299979A2 ALK ABELLO Controlled Release Antimicrobial Compositions And Methods For The Treatment Of Otic Disorders
Jul, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9205048 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders Apr, 2029

(6 years from now)

US9233068 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders Dec, 2029

(7 years from now)

US8318817 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders Apr, 2030

(7 years from now)

US9220796 ALK ABELLO Sterilization of ciprofloxacin composition Jul, 2035

(12 years from now)

US11040004 ALK ABELLO Otic gel formulations for treating otitis externa Nov, 2037

(15 years from now)

Treatment: Treatment of pediatric patients with otitis media with effusion undergoing tympanostomy tube placement; Treatment of otic infection or inflammation; The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage
Strength Dosage Availability
6% (60MG/ML) INJECTABLE, SUSPENSION;OTIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.